Dyax Report issue

Contributed to NME For profit Phase 3
Founded: Burlington MA United States (1989)
Status: Acquired by Shire (2016) → now Takeda (2018)

Organization Overview

First Clinical Trial
2007
NCT00456508
First Marketed Drug
2009
ecallantide (Kalbitor)
First NDA Approval
2018
lanadelumab (takhzyro)
Last Known Activity
2018

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Dyax Corp. | DYAX CORP.

Active Ingredients

Marketed Drugs (2)

ecallantide (Kalbitor) (NDA)

lanadelumab (takhzyro) (2018 NDA)

Drugs in Phase 3 Trials (3)

ecallantide (Kalbitor) (5 trials)

lanadelumab (takhzyro) (2 trials)

phosphate (1 trial)

Indications

Approved Indications


 

Angioedemas, Hereditary

Experimental Indications (Clinical Trials, Phases 1-4)


 

Angioedema (Phase 3)

Angioedemas, Hereditary (Phase 3)

Blood Loss, Surgical (Phase 2)

Hemorrhage (Phase 2)

Hereditary Angioedema Types I and II (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 7
  • # of Trial APIs: 3